In contrast, for patients with high‐risk HR+/HER2‐breast cancer, only those with cT2 tumors saw an increase in NACT use during the study period, again suggesting that tumor downsizing may have been the driving force behind their management strategy. The gene discussed is ERBB2; the disease is breast cancer.